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Major histocompatibility complex (MHC) class II deficiency is a rare and fatal primary
combined immunodeficiency. It affects both marrow-derived cells and thymic epithelium,
leading to impaired antigen presentation by antigen presenting cells and delayed
and incomplete maturation of CD4+ lymphocyte populations. Affected children are
susceptible to multiple infections by viruses, Pneumocystis jirovecii, bacteria and
fungi. Immunological assessment usually shows severe CD4+ T-lymphocytopenia,
hypogammaglobulinemia, and lack of antigen-specific antibody responses. The
diagnosis is confirmed by absence of constitutive and inducible expression of MHC class
II molecules on affected cell types which is the immunologic hallmark of the disease.
Hematopoietic cell transplantation (HCT) is the only established curative therapy for MHC
class II deficiency but it is difficult as affected children have significant comorbidities at the
time of HCT. Optimization organ function, implementing a reduced toxicity conditioning
regimen, improved T-cell depletion techniques using serotherapy and graft manipulation,
vigilant infection surveillance, pre-emptive and aggressive therapy for infection and
newer treatments for graft-versus-host disease have improved the transplant survival
for children with MHC class II deficiency. Despite persistent low CD4+ T-lymphopenia
reported in post-HCT patients, transplanted patients show normalization of antigen-
specific T-lymphocyte stimulation and antibody production in response to immunization
antigens. There is a need for a multi-center collaborative study to look at transplant
survival of HCT and long-term disease outcome in children with MHC class II deficiency
in the modern era of HCT.
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KEYPOINTS
- MHC class II deficiency is a form of severe combined immunodeficiency—urgent referral should
be made once the diagnosis is suspected.
- Severe and chronic viral infections are the hallmarks of the disease.
- The most prominent immunologic features are the absence or very low HLA-DR expression on
lymphocytes, with reduced CD4+ T-lymphocyte counts leading to an inverted CD4/CD8 ratio.
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- Early diagnosis of MHC class II deficiency is important
to enable prompt referral to a specialized center for
hematopoietic cell transplantation before occurrence of end
organ damage secondary to recurrent infection.
INTRODUCTION
Major histocompatibility complex (MHC) class II deficiency,
also known as bare lymphocyte syndrome type II, is a rare
autosomal recessive combined immunodeficiency and was first
described in 1980s (1). MHC class II molecules are pivotal for
the adaptive immune system and guide the development and
function of CD4+ T-lymphocytes. The immunologic hallmark
of the disease is the absence of constitutive and inducible
expression of MHC class II molecules on all cell types which
leads to impaired antigen presentation by HLA-DR, HLA-DQ,
and HLA-DP molecules on antigen presenting cells (APC)
(2). Besides affecting marrow-derived cells, the lack of MHC
class II expression on thymic epithelium also leads to delayed
and incomplete maturation of CD4+ T-lymphocytes. MHC
class II-mediated peptide presentation is essential for positive
and negative selection of the CD4+ T-lymphocyte population
in thymus, and for the homeostasis of the mature CD4+
T-lymphocyte population in the periphery. Overall, MHC class
II deficiency leads to combined immunodeficiency with defective
CD4+ T-lymphocyte maturation and activation and a lack of
T helper lymphocyte-dependent antibody production by B-
lymphocytes, resulting in significant susceptibility to severe
infections and frequently death in early childhood (3). The
reported incidence of MHC class II deficiency ranges from 5%
of SCID in Canada to 20–30% of SCID in Kuwait and in North
Africans Countries (4, 5).
MHC CLASS II DEFICIENCY AND
GENETICS
The MHC class II genes are located on chromosome 6 and
transcription is tightly regulated according to a strict-cell-type-
specific and quantitatively modulated pattern. Their expression
is largely restricted to thymic epithelial cells and APC that are
dendritic cells, macrophages and B-lymphocytes. In MHC class
II deficiency, the MHC locus itself is intact in patients and
FIGURE 1 | Molecular defects in patients with MHC class II deficiency. Four different transcription factors on MHC class II promoters have been associated with MHC
class II deficiency.
it is a monogenic disease caused by mutations in the genes
encoding for four regulatory factors controlling transcription of
MHC class II genes. These regulatory factors are CIITA (class
II transactivator), RFX5 (regulatory factor 5), RFXAP (RFX-
associated protein), and RFXANK (RFX-associated ankyrin-
containing protein) (Figure 1).
CIITA, which accounts for 15% of MHC class II deficiency, is
an inducible factor that controls the expression of MHC class II
gene expression by binding to the RFX complex and triggering
transcription. The RFXANK, RFX5, and RFXAP proteins are
subunits of the ubiquitously expressed RFX complex, which
binds directly to the promoters of all MHC class II genes and
together with other pleiotropic factors, forms the MHC class II
expression enhanceosome (6). Over 85% of affected children have
mutations in genes encoding for RFX complex and half of the
reported cases have RFXANK deficiency.
SPECTRUM OF DISEASE IN CHILDREN
WITH MHC CLASS II DEFICIENCY
Although MHC class II deficiency is not considered a
classical severe combined immunodeficiency (SCID) according
to the International Union of Immunological Societies (IUIS)
classification criteria, patients usually present with a clinical
phenotype that is very similar to SCID (7). Infectious
susceptibility is broad toward viruses (e.g., cytomegalovirus,
herpes simplex), bacteria (e.g., Staphylococcus sp., Streptococci
sp., Pseudomonas sp., Salmonella sp.), fungi (e.g., Candida sp.),
and protozoa (e.g., Pneumocystis jirovecii). These infections affect
the gastrointestinal, pulmonary, respiratory tracts, beginning in
the first year of life. Severe and chronic viral infections are the
hallmarks of the disease and are associated with a poor prognosis.
Recurrent bronchopulmonary infections caused by bacteria,
viruses and Pneumocystis jirovecii are frequently observed.
Older children may present with organ impairments such as
chronic lung disease, chronic diarrhea with malabsorption and
growth faltering. Intestinal and hepatic involvement caused by
Crytosporidium colonization has been reported in patients with
MHC class II deficiency; patients may develop chronic liver
disease secondary to cryptosporidium infection. The absence
of generalized BCGitis in these patients might in part be
accounted for by the presence of residual immunity in the form
of CD8+ T-lymphocytes and natural killer cells. Autoimmune
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manifestations such as autoimmune cytopenia have been
observed in 20% of patients with MHC class II deficiency (8).
DIAGNOSIS AND IMMUNOLOGIC
FEATURES OF CHILDREN WITH MHC
CLASS II DEFICIENCY
Patients with MHC class II deficiency generally have severe
CD4+ T-lymphocytopenia, hypogammaglobulinemia and lack
of antigen-specific antibody responses. Proliferations to mitogen
are usually conserved while absent to antigen. The hallmark
finding on lymphocyte phenotypes is the absence or very low
HLA-DR expression on lymphocytes, with decreased CD4+
T-lymphocyte counts leading to an inverted CD4/CD8 ratio
(Figure 2). The CD4+ lymphocytopenia reflects the abnormal
CD4+ thymocyte development, resulting from defective MHC
class II expression in the thymus. CD8+ T-lymphocyte counts
may be normal or low. T cell receptor excision circles (TREC)
has been reported to be measurable in some affected patients and
the diagnosis can be missed in TREC-based newborn screening
for severe combined immunodeficiency (9–11).
APPROACH TO HAEMATOPOIETIC CELL
TRANSPLANTATION IN CHILDREN WITH
MHC CLASS II DEFICIENCY
The natural history of non-transplanted patients is dismal with
a mean age of death at 4 years of age and the main cause of
death is overwhelming viral infection (12). Very few children
reach puberty and survive into adulthood (13). There are no
clear differences in prognosis among patients harboring the four
different genetic defects. Currently the only known cure forMHC
class II deficiency is allogeneic hematopoietic cell transplantation
(HCT). Historically this has only been reluctantly offered due
to the high risk of transplant-related morbidity and mortality.
Additionally, HCT for MHC class II deficiency is challenging
as many children have significant comorbidities at the time of
HCT. Transplant strategies to optimize the transplant survival of
patients with MHC class II deficiency can be divided into three
phrases: (1) pre-transplant phase; (2) transplant phase; and (3)
post-transplant phase.
PRE-TRANSPLANT PHASE
As younger age at HSCT has been consistently shown to be
associated with improved survival in children with primary
immunodeficiency, HCT should be performed as early as possible
before the onset of organ damage from multiple infections.
Some patients with MHC class II deficiency can be detected
used TREC-based newborn screening assays, and the diagnosis
confirmed by looking for MHC class II expression (9–11). Once
the diagnosis of MHC class II deficiency is suspected, a child
should be referred promptly to an expert team for evaluation
and confirmation of the diagnosis. The transplant process
should be initiated and performed as soon as possible. Patients
might require treatment of infections, respiratory supports
and nutritional rehabilitation to optimize their organ function
prior to HCT. A multidisciplinary team with participation
of respiratory physicians, gastroenterologists, dietitians, play
therapies and other supportive groups are required in all the
phases in order to achieve the best outcome possible.
TRANSPLANT PHASE
This consists of donor selection, appropriate stem cell source and
optimal conditioning regimen. As graft-vs. -host disease confers
no benefit to patients with MHC class II deficiency, the best
HLA-matched donor is a sibling or matched family donor. If no
family donor is found, a search of the national or international
FIGURE 2 | Flow cytometry of a patient MHC class II deficiency. Pre-transplant (A) flow cytometry shows absence HLA-DR and post-transplant (B) flow cytometry
shows presence of HLA-DR.
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TABLE 1 | Outcome of allogeneic hematopoietic cell transplantation for MHC class II deficiency.
References Year of HCT No. of
patients
Median age
at HCT,
months
(range)
Donor and stem
cell source
Conditioning regimen GvHD
prophylaxis
Stem cell doses Grade II-IV
aGvHD
cGvHD OS (%)
Elfeky et al.
(19)
NA 6 25 (12–38) 2 10/10 UCB
4 9/10 UCB
Flu 150 mg/m2
Treo 42 g/m2
No serotherapy
CSA+MMF Median CD34 2.1 ×
105/kg
4 (67%) 2 100
Small et al.
(15)
1990–2013 16 12 (6–48) 10 MMFD
4 MUD
2 UCB
5 marrow
2 PBSC
1 TCD marrow
6 TCD PBSC
TCD marrow/PBSC
Bu 16 mg/kg + Flu + Thiotepa or
Bu 16 mg/kg + Thiotepa + Cy
Bu 16 mg/kg + Flu + Cy
Bu 16 m/kg + Cy
Unmodified marrow/PBSC
Bu + Flu + Cy or
Thiotepa +Cy or
Melphalan + Flu + anti-CD52
Flu + Cy, anti-CD45 and anti-CD52
or
Low dose Cy + Flu + 200cGy TBI
UCB
Flu + Treo without serotherapy
CSA + MMF NA 4 (25%) 1 post
2nd HCT
69
Al-Mousa
et al. (17)
1994–2007 30
(3 had
second HCT)
27 (1–120) 26 MFD marrow
3 MMFD marrow
1 UCB
Bu 16 mg/kg + Cy 200 mg/kg +
VP16 300 mg/m2 or
Bu 16 mg/kg +Cy 200 mg/kg + ATG
Cy 200 mg/kg + TBI or
Flu 150 mg/m2 + melphalan 140
mg/m2 +ATG
CSA + MTX
or CSA or
CSA +
steroid
Median CD34 8.3 ×
106/kg (3–20.7 ×
106/kg)
MAC
9 grade II-III skin
aGvHD
5 grade II-III gut
aGvHD
1 lung GvHD
RIC
7 grade I-II aGvHD
3 66
Siepermann
et al. (20)
NA 1 18 7/10 UCB Bu 20 mg/kg + Flu 160 mg/m2 + Cy
120 mg/kg + ATG
CSA TNC 9 × 107/Kg Grade I aGvHD No Alive
Renella et al.
(21)
1981–2004 15
(2 had
second HCT)
18 (4–65) 13 MFD marrow
2 MUD marrow
All 2 second HCT
used MSD
Bu 16–20 mg/kg + Cy 200 mg/kg
+ ATG in MUD
CSA + MTX Median TNC: 4.3 ×
109/kg (3.3 × 108/kg
to 5.5 × 109/kg)
7 (47) 2 53
Saleem et al.
(3)
1991–1999 6
(2 had
second HCT)
6.5 (1–15.6
years)
5 MFD
1 MUD
Bu 16–20 mg/kg + Cy 200 mg/kg ±
Alemtuzumab ± ATG ±
anti-LFA-1/CD2 or Flu + Melphalan
CSA Median TNC: 5.9 ×
108/kg (1–11.5108/kg)
NA NA 33
Godthelp
et al. (22)
1993–1995 2 8, 23 2 MFD marrow Bu 20 mg/kg + Cy 200 mg/kg CSA + MTX TNC 2.5–4.6 × 108/kg None None Both alive
Bonduel et al.
(23)
1994 1
(had 2 HCT)
22 MMUD TCD
marrow
Bu 20 mg/kg + Cy 200 mg/kg +
anti-LFA1 + anti-CD2
CSA TNC 0.2 × 108/kg Grade II GvHD None Alive after
second
sibling CBT
(Continued)
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unrelated donor registries should be undertaken. Parental
haploidentical donors with newer methods of T-lymphocyte
depletion have emerged as promising alternative donors while
classic haploidentical HSCT with CD34+ selection have shown
high rate of non-engraftment in historical series (13–16).
The use of myeloablative reduced-toxicity conditioning (RTC)
is preferred in children with MHC class II deficiency as many
patients have multiple chronic infections and organ damage at
the time of HCT. RTC reduces early transplant complications and
late effects such as infertility. In addition, full donor chimerism is
not mandatory since stable mixed chimerism on lymphoid and
myeloid compartments have been reported to achieve long-term
cures. Experiences with reduced intensity conditioning (RIC) are
limited. Al-Mousa et al. reported 12 patients transplanted mainly
with intra-familial geno-identical donor after a RIC (flu-mel and
ATG) and reported mixed lymphoid and myeloid chimerism
in all patients but sufficient to cure the disease (17). Outside
a geno-identical donor, RIC needs to be used with caution.
Based on the current evidence, the European Society for Blood
and Marrow Transplant developed a guideline for patients with
primary immunodeficiencies (PID) (18). Bone marrow has been
the conventional source of stem cells but peripheral blood stem
cells have been increasingly used together with RTC to improve
donor chimerism (19).
POST-TRANSPLANT PHASE
In this phase, the main tasks are monitoring of donor
graft, surveillance of transplant-related complications and
rehabilitation of pre-transplant organ damage.
OUTCOME AND IMMUNE
RECONSTITUTION AFTER
HAEMATOPOIETIC CELL
TRANSPLANTATION IN CHILDREN WITH
MHC CLASS II DEFICIENCY
More than 100 transplants have been reported worldwide
(Table 1) (3, 14, 15, 17, 20, 21, 23–26). Patients with MHC
class II deficiency are difficult to transplant with increased
regimen-related toxicities, serious infections, graft rejection, and
GvHD. The conditioning protocols used in these patients were
variable and the majority of patients were conditioned with
Busulfan-based myeloablative conditioning. In the early reports,
the transplant survival was poor compared to those seen in
patients with other PIDs, with a survival rate of 50% or less
(3, 14, 21, 23, 24). Recently, a better transplant outcome has
been reported, the overall survival ranges 66–100% and reduced
toxicity conditioning has been increasingly used in these reports.
(15, 17, 26). A high incidence of acute graft-versus-host disease
has been reported in these patients and this can be accounted by
lack of in-vivo T-lymphocyte depletion with serotherapy. High
rate of chronic persistent viral infections before transplantation
may also increase the risk of GVHD. Patients undergoing HCT
before 2 years of age had better prognosis (14).
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Among HSCT long-term survivors, persistent CD4+ T-
lymphocytopenia has been observed in post-HCT patients. This
observation can ben explained by impaired thymic maturation
resulting from defective MHC class II expression on thymic
epithelia. Although the CD4+ T-lymphocyte number is low,
transplanted patients show normalization of antigen-specific T-
lymphocyte stimulation and antibody production in response to
vaccination. Partial engraftment post-HCT has been associated
with impaired immune repertoire (22).
SUMMARY
MHC class II deficiency is rare but invariably fatal primary
immunodeficiency. Allogenic HCT is the only curative treatment
and is considered the treatment of choice. Pre-transplant
treatment of infections and optimization of nutritional status
and organ function are important to improve transplant
survival. Transplant survival has improved with reduced toxicity
conditioning regimen, better donor availability, improved
supportive care, andmore effective anti-microbial therapy. There
is a need for a multi-center study to delineate the predictors
of outcome of HCT in MHC class II deficiency in the modern
era of HCT. Advances in gene therapy may be attractive as a
potential therapeutic alternative for children with MHC class II
deficiency (27, 28).
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